Michihiko Kuwano Selected Research

Michihiko Kuwano Research Topics

Disease

69	Neoplasms (Cancer) 01/2022 - 02/2002
18	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2004
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 04/2004
15	Breast Neoplasms (Breast Cancer) 01/2020 - 02/2003
9	Carcinoma (Carcinomatosis) 10/2013 - 12/2002
6	Hepatocellular Carcinoma (Hepatoma) 07/2016 - 05/2006
5	Neoplasm Metastasis (Metastasis) 12/2008 - 01/2003
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2014 - 07/2008
4	Hypoxia (Hypoxemia) 09/2010 - 07/2003
3	Stomach Neoplasms (Stomach Cancer) 05/2013 - 08/2010
3	Osteosarcoma (Osteogenic Sarcoma) 09/2010 - 02/2002
3	Pancreatic Neoplasms (Pancreatic Cancer) 05/2010 - 06/2006
3	Ovarian Neoplasms (Ovarian Cancer) 02/2009 - 11/2002
2	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 08/2011
2	Colorectal Neoplasms (Colorectal Cancer) 07/2016 - 05/2005
2	Carcinogenesis 10/2013 - 07/2003
2	Melanoma (Melanoma, Malignant) 06/2009 - 01/2008
2	Corneal Neovascularization 09/2007 - 12/2003
2	Thyroid Neoplasms (Thyroid Cancer) 04/2006 - 07/2003
2	Retinoblastoma (Glioblastoma, Retinal) 12/2005 - 02/2005
2	Urinary Bladder Neoplasms (Bladder Cancer) 07/2002 - 04/2002
1	Triple Negative Breast Neoplasms 01/2020

Drug/Important Bio-Agent (IBA)

32	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
19	ErbB Receptors (EGF Receptor)IBA 09/2017 - 04/2004
16	Gefitinib (Iressa)FDA Link 03/2015 - 05/2002
15	Pharmaceutical PreparationsIBA 01/2022 - 04/2002
12	Messenger RNA (mRNA)IBA 01/2014 - 02/2002
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 03/2002
9	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2017 - 12/2006
8	Tyrosine Kinase InhibitorsIBA 01/2012 - 05/2002
8	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2008 - 04/2002
7	Phosphotransferases (Kinase)IBA 05/2019 - 02/2005
7	Transcription Factors (Transcription Factor)IBA 05/2019 - 11/2002
5	Carrier Proteins (Binding Protein)IBA 01/2020 - 11/2002
5	Epidermal Growth Factor (EGF)IBA 04/2011 - 02/2002
5	Cisplatin (Platino)FDA LinkGeneric 08/2009 - 08/2002
5	Fluorouracil (Carac)FDA LinkGeneric 10/2008 - 12/2006
5	Adenosine Triphosphate (ATP)IBA 05/2005 - 11/2002
5	multidrug resistance-associated protein 1IBA 05/2005 - 04/2002
4	Biomarkers (Surrogate Marker)IBA 12/2018 - 09/2009
4	matrigelIBA 01/2014 - 06/2006
4	Indicators and Reagents (Reagents)IBA 05/2012 - 07/2002
4	Small Interfering RNA (siRNA)IBA 05/2012 - 03/2008
4	NF-kappa B (NF-kB)IBA 05/2010 - 09/2007
4	TubulinIBA 08/2009 - 06/2007
4	Antineoplastic Agents (Antineoplastics)IBA 01/2008 - 04/2002
3	ATP-Binding Cassette Transporters (ABC Transporters)IBA 05/2019 - 12/2002
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2017 - 03/2002
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 08/2014 - 12/2003
3	CytokinesIBA 08/2013 - 11/2005
3	Trastuzumab (Herceptin)FDA Link 05/2013 - 12/2005
3	AntibodiesIBA 01/2012 - 09/2004
3	CalciumIBA 09/2010 - 11/2003
3	Cadherins (E-Cadherin)IBA 02/2010 - 07/2002
3	Paclitaxel (Taxol)FDA LinkGeneric 06/2009 - 07/2007
3	NickelIBA 12/2008 - 07/2003
3	Estrogen Receptor alphaIBA 03/2008 - 05/2006
3	Protein Kinase CIBA 01/2008 - 02/2005
3	Biological ProductsIBA 11/2007 - 02/2002
2	osimertinibIBA 01/2022 - 09/2017
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020 - 01/2017
2	Growth Factor ReceptorsIBA 05/2019 - 09/2009
2	AfatinibIBA 09/2017 - 08/2014
2	Everolimus FDA Link 07/2016 - 01/2014
2	InterleukinsIBA 01/2014 - 12/2007
2	AntioxidantsIBA 10/2013 - 10/2008
2	PeroxiredoxinsIBA 10/2013 - 10/2008
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 08/2013 - 12/2007
2	CXC ChemokinesIBA 08/2013 - 05/2010
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 08/2013 - 10/2008
2	Lapatinib (GW572016)FDA Link 05/2013 - 01/2008
2	Angiogenesis InhibitorsIBA 07/2012 - 10/2008
2	Threonine (L-Threonine)FDA Link 09/2011 - 05/2010
2	Y-Box-Binding Protein 1IBA 08/2011 - 11/2004
2	EnzymesIBA 08/2010 - 10/2008
2	Thymidine PhosphorylaseIBA 08/2010 - 05/2002
2	DNA (Deoxyribonucleic Acid)IBA 07/2010 - 06/2010
2	NF-KappaB Inhibitor alphaIBA 05/2010 - 06/2009
2	Carboplatin (JM8)FDA LinkGeneric 06/2009 - 07/2007
2	taxaneIBA 02/2009 - 06/2007
2	Thrombospondin 1IBA 10/2008 - 02/2002
2	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 10/2008 - 12/2006
2	Interferon-alpha2bIBA 10/2008 - 10/2006
2	Liposomes (Liposome)IBA 08/2008 - 12/2007
2	Multidrug Resistance-Associated ProteinsIBA 04/2008 - 04/2002
2	Taxoids (Taxanes)IBA 01/2008 - 06/2007
2	Dexamethasone (Maxidex)FDA LinkGeneric 09/2007 - 08/2005
2	Complementary DNA (cDNA)IBA 06/2006 - 12/2004
2	Mitogen-Activated Protein KinasesIBA 04/2006 - 02/2005
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 04/2006 - 02/2005
2	Mitogen-Activated Protein Kinase 3IBA 12/2005 - 04/2004
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2005 - 04/2002
2	Semaxinib (SU5416)IBA 05/2002 - 03/2002
1	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 05/2019
1	Androgen Receptors (Androgen Receptor)IBA 05/2019
1	Oncogene Proteins (Oncogene Protein)IBA 05/2019
1	ChromatinIBA 05/2019

Therapy/Procedure

18	Therapeutics 01/2020 - 01/2003
5	Drug Therapy (Chemotherapy) 06/2009 - 04/2002
2	Aftercare (After-Treatment) 09/2011 - 10/2008